<DOC>
	<DOCNO>NCT02065791</DOCNO>
	<brief_summary>The goal study ass whether canagliflozin renal vascular protective effect reduce progression renal impairment relative placebo participant type 2 diabetes mellitus ( T2DM ) , Stage 2 3 chronic kidney disease ( CKD ) macroalbuminuria , receive standard care include maximum tolerated label daily dose angiotensin-converting enzyme inhibitor ( ACEi ) angiotensin receptor blocker ( ARB ) .</brief_summary>
	<brief_title>Evaluation Effects Canagliflozin Renal Cardiovascular Outcomes Participants With Diabetic Nephropathy</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double-blind ( neither physician participant know identity assign treatment ) , placebo-controlled ( inactive substance compare medication test whether medication real effect ) , parallel-group , multicenter study effect canagliflozin renal cardiovascular outcome participant type 2 diabetes mellitus ( T2DM ) diabetic nephropathy , receive standard care include maximum tolerated daily dose angiotensin-converting enzyme inhibitor ( ACEi ) angiotensin receptor blocker ( ARB ) . The study consist pretreatment phase ( several week ) , double-blind treatment phase ( approximately 66 month ) . During pretreatment phase participant also receive diet/exercise counseling lipid blood pressure management well counsel renal cardiovascular ( CV ) risk factor medication . A post-treatment follow-up contact visit take place approximately 30 day last dose study drug completion study . The total duration study estimate 5 5.5 year . Approximately 4,200 participant randomize 1:1 ratio canagliflozin match placebo . Participants randomize canagliflozin receive dose 100 mg daily . The overall safety tolerability canagliflozin evaluate collect information adverse event , laboratory test , vital sign ( pulse , blood pressure ) , physical examination , body weight .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Type 2 diabetes mellitus hemoglobin A1c ( HbA1c ) great equal ( &gt; = ) 6.5 percent ( % ) less equal ( &lt; = ) 12.0 % , estimate glomerular filtration rate ( eGFR ) &gt; = 30 milliliter ( mL ) /minute ( min ) /1.73meter ( ) ^2 le ( &lt; ) 90 mL/min/1.73 m^2 Participants need stable maximum tolerate labeled daily dose angiotensinconverting enzyme inhibitor ( ACEi ) angiotensin receptor blocker ( ARB ) least 4 week prior randomization Must urine albumin creatinine ratio ( UACR ) great ( &gt; ) 300 milligram ( mg ) /gram ( g ) &lt; = 5000 mg/g History diabetic ketoacidosis type 1 diabetes mellitus History hereditary glucosegalactose malabsorption primary renal glucosuria Renal disease require treatment immunosuppressive therapy Known significant liver disease Current history New York Heart Association ( NYHA ) Class IV heart failure Blood potassium level &gt; 5.5 millimole ( mmol ) /liter ( L ) Screening</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Diabetic Nephropathies</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>End-Stage Kidney Disease</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Macroalbuminuria</keyword>
</DOC>